Alzheimer's Partnerships: Sharing Risks, Chasing Potentially Huge Rewards
Executive Summary
Even now, decades after the first scientifically informed hypotheses about what causes Alzheimer's disease (AD), no consensus and thus no clear path towards treatment exists. Offsetting the uncertainty is the knowledge that a truly effective treatment would be a smashing success - potentially generating double-digit billions in annual global revenues
You may also be interested in...
Roche Takes Back Evotec's EVT-302 To Develop In Alzheimer's Disease, In $800 Million Deal
Evotec and Roche are to collaborate on the development of the MAO-B inhibitor, EVT-302, for Alzheimer's disease, a compound that previously failed in another indication, as an aid to smoking cessation.
Bristol's Early Alzheimer's Research Takes A Different Tack
Like many other drug makers, Bristol-Myers Squibb has its eye on the potentially lucrative market for a disease-modifying Alzheimer's disease therapy. During an investor meeting March 4, management highlighted the early- to mid-stage Alzheimer's pipeline and outlined one novel approach: targeting the disease earlier before Alzheimer's symptoms develop
Bristol's Early Alzheimer's Research Takes A Different Tack
Like many other drug makers, Bristol-Myers Squibb has its eye on the potentially lucrative market for a disease-modifying Alzheimer's disease therapy. During an investor meeting March 4, management highlighted the early- to mid-stage Alzheimer's pipeline and outlined one novel approach: targeting the disease earlier before Alzheimer's symptoms develop